RxDoctor Payments DataLook up a doctor →

Shaker Dakhil, MD

Hematology & Oncology · Wichita, KSNPI 1417918079

Payments from drug & device makers

$11,239,329in general payments, 2019–2025

Across 2,851 payments — averaging $3942.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$4.7M
  • E.r. Squibb & Sons, L.L.C.$1.9M
  • Eli Lilly$644K
  • Genentech, Inc.$525K
  • Acerta Pharma LLC$509K
  • Amgen$475K
  • plus $2.5M from 54 others
$80,798in research payments, 2019–2025

Across 9 payments — averaging $8977.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$63K
  • Aurobindo Pharma USA, Inc.$17K
  • Novartis$470

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis190$4,688,817
E.r. Squibb & Sons, L.L.C.176$1,918,536
Eli Lilly34$643,857
Genentech, Inc.154$524,887
Acerta Pharma LLC25$508,513
Amgen74$474,850
AstraZeneca(2 entities)140$395,325
Merck195$367,456
Beigene, Ltd.23$246,908
Daiichi Sankyo Inc.130$180,381
Roche Products Limited49$143,724
Astrazeneca UK Limited10$129,274
US Oncology Corporate, Inc.5$120,070
Morphosys AG13$92,614
Mirati Therapeutics, Inc.39$92,249
Regeneron19$80,800
Incyte Corporation30$53,574
Bristol Myers Squibb93$53,239
Pfizer149$52,937
Hoffmann-la Roche Limited11$43,540
GSK59$36,733
Eisai Inc.68$34,632
Dova Pharmaceuticals16$33,316
AbbVie104$32,969
Helsinn Healthcare SA10$31,887
Mckesson Specialty Care Distribution, LLC1$30,000
Tesaro, Inc.12$22,737
Gilead(2 entities)82$21,462
Jazz Pharmaceuticals Inc.30$20,380
Beone Medicines Ltd.6$17,546
Janssen Research & Development, LLC3$16,691
Johnson & Johnson50$13,648
Seagen Inc.74$13,576
Takeda Pharmaceuticals U.S.A., Inc.25$12,305
Astellas Pharma US Inc34$10,746
Tolmar, Inc.4$10,017
Spectrum Pharmaceuticals Inc.4$9,640
EMD Serono, Inc.31$8,923
Astellas Pharma Global Development4$5,092
AMAG Pharmaceuticals, Inc.13$4,995
Mylan Institutional Inc.19$4,155
Bayer46$4,095
Fresenius Kabi USA, LLC1$3,150
Taiho Oncology, Inc.18$2,565
Epizyme, Inc.12$2,294
Morphosys, US Inc.4$1,849
AVEO Pharmaceuticals, Inc.17$1,785
Verastem, Inc.6$1,492
Coherus Oncology, Inc.5$1,425
Athenex Pharmaceutical Division, LLC1$1,250
Geron Corporation3$1,225
Genentech USA, Inc.64$1,188
Sobi, Inc13$1,164
Rigel Pharmaceuticals, Inc.16$1,059
Karyopharm Therapeutics Inc.15$1,024
Janssen Scientific Affairs, LLC1$1,010
Array Biopharma Inc19$944
Halozyme Inc1$900
Eagle Pharmaceuticals, Inc.1$850
Sanofi48$762

How this compares

$11,239,329 in reported general payments places this provider in the 95th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas →

Medicare billing

Part B allowed, 2024
$11,259,976
Medicare patients
1,413
Services billed
473,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Wichita

See the full list for Kansas →

Where these figures come from

Is this you, or does something look wrong? →